- Home
- DRCT vs VTVT Comparison
DRCT vs VTVT Comparison
Compare DRCT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRCT | VTVT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 127.0M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DRCT | VTVT |
|---|---|---|
| Price | $0.07 | $36.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $43.50 |
| AVG Volume (30 Days) | ★ 30.0M | 12.7K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,369,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $13.15 |
| 52 Week High | $6.59 | $36.99 |
Technical Indicators
Market Signals| Indicator | DRCT | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 68.16 |
| Support Level | $0.06 | $33.75 |
| Resistance Level | $0.08 | $36.03 |
| Average True Range (ATR) | 0.01 | 2.25 |
| MACD | 0.00 | 0.37 |
| Stochastic Oscillator | 11.01 | 87.47 |
Price Performance
Historical ComparisonAbout DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.